However, ADAMTS13 activity levels are often not readily available at the time of presentation in a patient with evidence of MAHA; and in the vast majority of clinical scenarios, the clinician must decide to initiate risky but life-saving therapy before having laboratory confirmation of a TTP diagnosis. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.